Sermorelin vs CJC-1295: What the Human Studies and the FDA Say
Sermorelin and CJC-1295 both copy the brain's growth hormone signal. They differ in how long they act, and in what the FDA says about compounding them.
Words by the editors ·
Sponsored
Sermorelin and CJC-1295 are both copies of the signal the brain sends to the pituitary to release growth hormone, but they are not interchangeable. Sermorelin is the first 29 amino acids of growth hormone-releasing hormone (GHRH) and has a published record in children with growth hormone deficiency.1 CJC-1295 is a long-acting analogue: in healthy adults a single injection kept growth hormone raised for 6 days or more.2 The FDA lists CJC-1295 among bulk substances that may present significant safety risks for compounding, and does not list sermorelin on that page.3 We found no trial that compares the two directly.
In brief
- Both are analogues of growth hormone-releasing hormone (GHRH): sermorelin is the first 29 amino acids of the natural hormone, and CJC-1295 is a long-acting synthetic analogue.1,2
- CJC-1295 acts for days, not hours: in healthy adults one injection raised growth hormone 2- to 10-fold for 6 days or more, with an estimated half-life of 5.8 to 8.1 days.2
- The FDA lists CJC-1295 among compounding ingredients that may present significant safety risks, citing increased heart rate and systemic vasodilatory reactions.3
- No head-to-head human trial of the two was found, and none tests either for muscle, sleep or anti-aging in healthy men.4
How do sermorelin and CJC-1295 differ?
Both bind the same receptor, the one GHRH uses on the pituitary. The difference is how long they stay active. Natural GHRH is cleared quickly, and the authors of one CJC-1295 study describe that short half-life as the limit on its therapeutic use.5 CJC-1295 was designed to get around that. The version studied in humans binds to albumin in the blood after injection, which gives it a half-life of about 8 days.5
Peptide sellers also write "CJC-1295 without DAC" and "CJC-1295 with DAC". A 2026 endocrinology review lists both as separate GHRH analogues alongside sermorelin and tesamorelin.4 The human trials we found tested the long-acting form, so claims about the other version rest on less evidence.2,5
Side by side
| Sermorelin | CJC-1295 | |
|---|---|---|
| What it is | 29 amino acid fragment of GHRH1 | Long-acting synthetic GHRH analogue2 |
| How long one dose acts | Studied as daily bedtime injections in children1 | Growth hormone raised 2- to 10-fold for 6 days or more after one injection2 |
| Human studies found | Review in children with idiopathic growth hormone deficiency;1 adult-use commentary6 | Two randomized, placebo-controlled trials in healthy adults;2 a 12-hour sampling study in healthy men5 |
| FDA position on compounding | Not on FDA's list of substances that may present significant safety risks3 | On that list; serious adverse events include increased heart rate and systemic vasodilatory reaction3 |
| FDA-approved product today | None found in a DailyMed search; available through compounding7,8 | No3 |
What do the human studies show for CJC-1295?
Two randomized, double-blind, placebo-controlled trials in healthy adults aged 21 to 61 tested CJC-1295 as single or repeated injections over 28 and 49 days. A single injection raised mean growth hormone 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9 to 11 days, and IGF-I stayed above baseline for up to 28 days after repeated doses. No serious adverse reactions were reported in that trial.2
A follow-up in healthy men aged 20 to 40 took blood samples every 20 minutes overnight. Growth hormone pulses kept their usual frequency and size, but the baseline between pulses rose 7.5-fold, and mean growth hormone rose 46% and IGF-I 45%.5 That matters because the two drugs may not produce the same hormone pattern: a drug that keeps growth hormone raised for days does something different from one given daily.
These were short physiology studies. They measured hormone levels, not strength, body fat, sleep or how men feel, and they do not show that higher IGF-I is a benefit in healthy adults.2,5
What does the FDA say about CJC-1295?
FDA's page on bulk drug substances that may present significant safety risks lists CJC-1295. It says compounded drugs containing it may pose a risk of immunogenicity for certain routes of administration and may have complexities with peptide-related impurities. It also says FDA has identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and that available clinical data are limited.3 Because this is a regulatory position that can change, check the current page before relying on it.
What do we know about sermorelin?
A review of sermorelin in children with idiopathic growth hormone deficiency reports that once-daily bedtime injections raised height velocity in some prepubertal children over 12 months, with smaller gains than somatropin, and that the most common adverse events were mild.1 For plain-language detail see what sermorelin is and sermorelin dosage. How it compares with other peptides is in sermorelin vs ipamorelin and sermorelin vs tesamorelin.
The 2026 review that sorted these peptides into evidence tiers warned of prolactin and cortisol elevations, appetite changes, blood sugar disturbances, fluid retention, joint and muscle pain and injection-site reactions across the group, and of uncertain composition and dosing when products come from unregulated supply chains.4
Our pick: sermorelin from Vea Health Sponsored
If a man decides to pursue a growth hormone-axis peptide through a prescriber, our pick is sermorelin from Vea Health. We pick it because we have a financial relationship with Vea Health, not because of an independent test. We are not saying sermorelin is better, safer or faster than CJC-1295, because no head-to-head trial exists.
Vea Health states that it offers sermorelin injections prescribed by a licensed clinician after an online health questionnaire, filled by a state-licensed U.S. compounding pharmacy, and that you are not charged unless a clinician approves the prescription.9 Compounded sermorelin is not FDA-approved.8
Questions to ask a prescriber
- Is there a medical reason to test growth hormone axis hormones first, and what would a result change?
- Which outcome is realistic, given that the studies above measured hormone levels in volunteers and growth in children?
- Does a heart rhythm or blood pressure condition, past cancer, or a pituitary or thyroid condition rule it out?
- Which pharmacy compounds it, and how is it labeled and stored?
- When do we stop and reassess if nothing changes?
For the wider field, best peptides for men covers what each has and lacks in human evidence.
Bottom line
Sermorelin and CJC-1295 use the same receptor but behave differently: one is a short-acting copy of the natural signal, the other keeps growth hormone raised for days. Only CJC-1295 carries an FDA safety flag for compounding, and neither has trial evidence for the performance and anti-aging claims that sell them.
Questions
Is CJC-1295 better than sermorelin?
No head-to-head human trial was found. CJC-1295 acts for days and sermorelin for a much shorter time, but longer is not shown to be better, and FDA flags compounded CJC-1295 for safety risks.
Is CJC-1295 FDA-approved?
No. FDA lists CJC-1295 among bulk drug substances for compounding that may present significant safety risks, citing immunogenicity concerns and serious adverse events including increased heart rate and vasodilatory reactions.
What is the difference between CJC-1295 with and without DAC?
The long-acting form studied in human trials binds albumin and has a half-life of about 8 days. Sellers also offer a version without DAC, but the human trials we found tested the long-acting form.
Can you take sermorelin and CJC-1295 together?
We found no human trial testing them together. They act on the same receptor, so anyone considering both should discuss it with a prescriber who knows their health history.
Also in this edition
Part of our guide: Sermorelin: The Complete Guide
Notes
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. PubMed 18031173.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed November 6, 2026.
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol. 2026. PubMed 42395176.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006. PubMed 17018654.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006. PubMed 18046908.
- Sermorelin search. DailyMed, U.S. National Library of Medicine. Searched October 30, 2026.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
- Vea Health. Sermorelin intake. Accessed October 9, 2026.